PE20021032A1 - Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata - Google Patents

Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata

Info

Publication number
PE20021032A1
PE20021032A1 PE2002000305A PE2002000305A PE20021032A1 PE 20021032 A1 PE20021032 A1 PE 20021032A1 PE 2002000305 A PE2002000305 A PE 2002000305A PE 2002000305 A PE2002000305 A PE 2002000305A PE 20021032 A1 PE20021032 A1 PE 20021032A1
Authority
PE
Peru
Prior art keywords
health
quality
alkyl
prostate cancer
trans
Prior art date
Application number
PE2002000305A
Other languages
English (en)
Spanish (es)
Inventor
Talat Ashraf
Amitabh Singh
Robert J Padley
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20021032A1 publication Critical patent/PE20021032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2002000305A 2001-04-11 2002-04-11 Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata PE20021032A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08

Publications (1)

Publication Number Publication Date
PE20021032A1 true PE20021032A1 (es) 2002-11-12

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000305A PE20021032A1 (es) 2001-04-11 2002-04-11 Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata

Country Status (10)

Country Link
EP (1) EP1379238A1 (pt)
JP (1) JP2005503339A (pt)
CN (1) CN1514727A (pt)
AR (1) AR033465A1 (pt)
BR (1) BR0205970A (pt)
CA (1) CA2442591A1 (pt)
IL (1) IL158071A0 (pt)
MX (1) MXPA03009277A (pt)
PE (1) PE20021032A1 (pt)
WO (1) WO2002085351A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
US20090054473A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL342500A1 (en) * 1997-08-04 2001-06-04 Abbott Lab Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists

Also Published As

Publication number Publication date
JP2005503339A (ja) 2005-02-03
BR0205970A (pt) 2003-09-30
WO2002085351A1 (en) 2002-10-31
AR033465A1 (es) 2003-12-17
CN1514727A (zh) 2004-07-21
EP1379238A1 (en) 2004-01-14
MXPA03009277A (es) 2004-03-10
IL158071A0 (en) 2004-03-28
CA2442591A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
UY27939A1 (es) Compuestos
RU2013111077A (ru) Дипептидное пролекарство, его применение и лекарственное средство
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
EE05302B1 (et) 4-fluoro-N-(indaan-2-l)bensamiidi kasutamine ja protsess ravimi valmistamiseks
RU2009114167A (ru) Комбинации специфических ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
PE20021032A1 (es) Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
SE0100569D0 (sv) New compounds
DE122009000036I1 (de) Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
SE9802206D0 (sv) Novel compounds
ATE364044T1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
DE602004015603D1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
AU8180001A (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
ATE516366T1 (de) Regulierte aptamer-therapeutika
PE20040578A1 (es) Derivados de 1-[(indol-3-il)carbonil]piperazina
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
EA200401586A1 (ru) Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста
EA200400707A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
AU2003210850A8 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
RU2008133287A (ru) Фармацевтическая гелесодержащая композиция для местного и наружного применения
RU2009127858A (ru) Фармацевтическая композиция, включающая алискирен и авосентан
SE0403118D0 (sv) New compounds 2
RU2002132883A (ru) Новые полициклические инданилимидазолы, обладающие альфа2 адренергической активностью

Legal Events

Date Code Title Description
FA Abandonment or withdrawal